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Abstract
Background: A selective, systematic, Internet-based, Chlamydia Screening Implementation for 16 to 29-year-old
residents started in three regions in the Netherlands in April 2008: in the cities of Amsterdam and Rotterdam and a
more rural region, South Limburg. This paper describes the evaluation design and discusses the implications of the
findings from the first screening round for the analysis. The evaluation aims to determine the effects of screening
on the population prevalence of Chlamydia trachomatis after multiple screening rounds.
Methods: A phased implementation or ‘stepped wedge design’ was applied by grouping neighbourhoods
(hereafter: clusters) into three random, risk-stratified blocks (A, B and C) to allow for impact analyses over time and
comparison of prevalences before and after one or two screening rounds. Repeated simulation of pre- and
postscreening Chlamydia prevalences was used to predict the minimum detectable decline in prevalence. Real
participation and positivity rates per region, block, and risk stratum (high, medium, and low community risk) from
the 1st year of screening were used to substantiate predictions.
Results: The results of the 1st year show an overall participation rate of 16% of 261,025 invitees and a positivity
rate of 4.2%, with significant differences between regions and blocks. Prediction by simulation methods adjusted
with the first-round results indicate that the effect of screening (minimal detectable difference in prevalence) may
reach significance levels only if at least a 15% decrease in the Chlamydia positivity rate in the cities and a 25%
decrease in the rural region after screening can be reached, and pre- and postscreening differences between
blocks need to be larger.
Conclusions: With the current participation rates, the minimal detectable decline of Chlamydia prevalence may
reach our defined significance levels at the regional level after the second screening round, but will probably not
be significant between blocks of the stepped wedge design. Evaluation will also include other aspects and
prediction models to obtain rational advice about future Chlamydia screening in the Netherlands.
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Chlamydia trachomatis is a sexually transmitted bacter-
ial infection that remains asymptomatic in most cases,
but it can cause serious complications later in life,
especially for women. Chlamydia screening pro-
grammes have been introduced to improve case find-
ing, but screening apparently healthy people remains
an area of considerable debate among public health
researchers, sexually transmitted infection (STI) specia-
lists, and policy makers [1-3]. Objectives of a screening
programme involve not only the level of individual
health (reducing complications through early diagnosis
and treatment), but also the level of public health
(reducing transmission within the population). The
body of evidence for the effectiveness of population
screening programmes is limited [4,5], and no convin-
cing evidence of the effectiveness of screening young
people for opportunistic Chlamydia exists [3,6]. Ran-
domized controlled trials (RCTs) that specifically focus
on population impact and thorough evaluations might
provide the evidence needed to justify widespread
population screening.
Chlamydia screening in the Netherlands
During 2002 and 2003 a pilot Chlamydia screening
program was undertaken in the Netherlands (Pilot Ct)
which showed a relatively high Chlamydia prevalence,
especially in highly urbanized regions [7]. These results
led the Dutch Ministry ofH e a l t ht oc o n s i d e ra
national Chlamydia screening programme on condi-
tion that sufficient insight into regional differences in
prevalences and proven effectiveness, cost-effective-
ness, and feasibility of screening would be obtained
[8,9]. To ascertain this, a Chlamydia screening pro-
gramme for 16 to 29-year-old residents started in
Amsterdam, Rotterdam, and South Limburg in April
2008. This is the first large-scale intervention that
pilots a selective, systematic, Internet-based, Chlamy-
dia screening, and it provides a unique opportunity to
gather evidence of the effectiveness of screening. The
set-up of the current screening programme facilitates
the in-depth evaluation necessary to decide whether
and how a national roll-out of Chlamydia screening in
the Netherlands can take place in the future. The use
of a randomized stepped wedge approach - as an alter-
native to an RCT - allows for the study of the impact
of a screening programme with at least two screening
rounds on outcome parameters such as the population
prevalence of Chlamydia and self-reported pelvic
inflammatory disease (PID). Here, we clarify the design
of our evaluation and discuss the implications of the
results of the first round for the final evaluation after
completion of two screening rounds.
Methods
Overview of the screening programme
The Chlamydia Screening Implementation (CSI) is
being implemented by the Public Health Services in
Amsterdam, Rotterdam, and South Limburg. STI AIDS
N e t h e r l a n d si sc o o r d i n a t i n gthe programme. In colla-
boration with these implementing parties, the Centre for
Infectious Disease Control at the National Institute for
Public Health and the Environment (RIVM) will provide
process and impact evaluations. The background and
set-up of CSI (including a flowchart) are explained in
detail elsewhere [10,11]. Briefly, the features are:
▪ Design: selective, systematic, population-based
screening.
▪ Invitees: in the 1st year, more than 261,000 people
aged 16 to 29 years, obtained from the population
register, are invited to participate. In Amsterdam
and Rotterdam where the population is dense, all
sexually active people are encouraged to participate,
but in South Limburg where the population is less
dense, eligibility for screening depends on the indivi-
dual’s score on a questionnaire (including e.g. sexual
history, residence area, ethnic background, and
symptoms) related to the expected Chlamydia risk
[12].
▪ Setting: invitation letters containing the website
address http://www.chlamydiatest.nl and a personal
login code are sent by mail. Communication and
screening procedures are Internet based. Home sam-
pling kits (urine or vaginal swab) can be requested
through this website.
▪ Intervention: Chlamydia test; advice and referral
letter for treatment (for Chlamydia-positive partici-
pants and current partners). Opportunity to notify
former partners anonymously through the website
http://www.chlamydiatest.nl.
▪ Follow-up: repeated invitation in two consecutive
periods of 1 year. Chlamydia-positive participants
automatically receive a test package 6 months after
the first test.
▪ Laboratory procedures: nucleic acid amplification
techniques (NAAT) in three regional accredited
laboratories [10].
▪ Data collection: data are stored in a central data-
base. For each invitee, demographic information
from the municipal database is combined with auto-
matically generated data from screening ‘steps’.T h e
data are uploaded from the laboratories and on-line
questionnaires filled in by the participants. The data
include age, gender, and client characteristics such
as self-reported sexual history and clinical
symptoms.
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The evaluation of the CSI consists of two main compo-
nents, both including various substudies:
▪ A process evaluation, which examines the extent
to which the programme is operating as intended by
assessing programme operations and determining
how well the target population has been reached
(non response and acceptability). The design of the
process evaluation and first results are described
elsewhere [11].
▪ Impact evaluation, which aims to assess the effec-
tiveness of screening on the prevalence of Chlamy-
dia in the target population. We describe this part
of the evaluation in more detail in this paper. The
cost-effectiveness will be addressed in another paper.
Impact evaluation
Participation and positivity rates evaluated in the
stepped wedge design
To evaluate the effects of screening on the main out-
come parameters, i.e. the participation rate (the pro-
portion of invitees who send a sample to the laboratory
and the estimated prevalence of Chlamydia), we chose
a phased implementation of the screening for randomly
selected groups. This stepped wedge design is defined
as a sequential roll-out over a number of periods; by
the end of the programme, all those eligible will have
received an invitation to participate, even though the
order is determined at random [13]. The design enables
estimating (a) the effect of one or two screening
rounds on the estimated population prevalence of
Chlamydia, (b) time trends in the participation rates of
the screening rounds, and (c) indirect effects of the
screening on groups not targeted in the first round
(spill-over effect). It will make estimating the pre- and
postscreening Chlamydia prevalences in these regions
possible. The Chlamydia positivity rate and the self-
reported PID in the screened population will be
assessed within the stepped wedge roll-out of the
screening in three randomly selected subgroups of the
target populations of each region (Figure 1). In both
Amsterdam and Rotterdam, one smaller group (block
A, one-sixth of the target population) will be offered
screening three times. The largest group (block B, two-
thirds of the population) will be offered screening
twice, and another smaller ‘control’ group (block C,
one-sixth of the population), only once, in a later
phase. Due to smaller populations to invite in South
Limburg, the three blocks are equal in size to maximize
the power of comparisons between groups. We prefer
the step-by-step implementation for the purpose of
logistics, since it is difficult to cover all regions at
once. The speed of the roll-out of the intervention is
adjusted to the number of invitations that can be
handled per day and the laboratory capacity.
To compare pre- and postintervention groups after
one and two screening rounds, the Chlamydia positivity
rates from blocks A1 and B1 of the first round (R1) will
be used to estimate the Chlamydia prevalences that will
serve as proxies for the prevalences in the target popula-
tion before the screening started (Figure 1). These ‘pre-
screening prevalences’ from A1 and B1 can be
compared with the ‘postscreening prevalences’ after the
first round (A2 and B2) and after two rounds (A3). The
prevalence estimate from the control group (C) is con-
sidered a proxy for the Chlamydia prevalence in a
group that has not received the intervention and will
also be used to estimate ‘secular time trends’ in
Figure 1 Stepped wedge design: schematic of the phased implementation of Chlamydia Screening Implementation in three blocks
(A,B, and C). The design enables comparison of prescreening (A1 and B1) and post-screening prevalences after the first round (A2 and B2)
and after the second round (A3)
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Chlamydia prevalence in an unscreened population.
Cluster randomization
Each region consists of different neighbourhoods (here-
after named clusters) which we used as the level of ran-
domisation. These clusters were defined by the
‘community risk level’ as high, medium or low on the
basis of age-profile (proportion of 16-29 years old), eth-
nic profile (proportions of Surinamese and Antillean
residents (known risk groups) [14], and income profile
(proportion in lower income category). In South Lim-
burg, the level of urbanization was also taken into
account.
The order of invitations is thus cluster randomized
instead of individually randomized. We expect the effect
of detection and treatment of Chlamydia cases to be
higher when geographical clusters are submitted to
screening in a short period. We predict cluster randomi-
zation to cover more social networks and sexual part-
nerships compared to individual randomization.
Furthermore, inviting all young people in one cluster at
the same time will minimize stigmatization and prevent
questions such as ‘why me?’.
Randomization of clusters is stratified within the
blocks A, B, and C by the expected risk levels for Chla-
mydia, so that the proportion of high-, medium-, and
low-risk clusters was similar for the blocks in each
region (Figure 2). Figure 3 and 4 illustrate this with the
stratification of clusters in Amsterdam and Rotterdam.
Power estimates and simulations of outcome
A significant decline in the Chlamydia prevalence after
one or two screening rounds would establish the effec-
tiveness of the screening programme. The magnitude of
the decline that can be assessed will depend on the
degree of participation and the Chlamydia positivity
rates. We tested the expected power of our design for
comparisons of prevalences with Monte Carlo simula-
tions of the outcomes of the screening rounds 1 and 2
for each of the regions (Amsterdam, Rotterdam, and
South Limburg) and for the blocks A, B, and C. The
purpose of these simulations was to determine how
many people have to participate in the screening for a
certain decline in Chlamydia prevalence to be
detectable.
Based on the Pilot Ct [7], we anticipated an overall
participation rate of 30% and an average positivity rate
of 4-6%. For the power calculations, the following
assumptions were made: (a) in all clusters, a similar
fraction of the population participates in the screening;
(b) the participating population is a random selection of
the invited population; (c) the hypothetical prevalence
rates per cluster vary from 0 to 10%, normally distribu-
ted around the average; and (d) after screening, we
expect a decline in Chlamydia prevalence.
Each simulation included the following steps: (1) simula-
tion of cluster prevalence between 0 and 10% with an
average of 4%, 5%, or 6% before screening; (2) simulation
of cluster prevalence with an average below 4%, 5%, or 6%
Figure 2 Number of clusters and invitees, by region, block and community risk level.
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the differences in prevalences. This procedure was
repeated 5000 times for various sample fractions (partici-
pation rates). The percentage of simulations with signifi-
cant differences (power) was calculated. Finally, contour
plots were made with expected participation rates against
the decline in mean prevalence after one or two screening
rounds, per region, (a) for the whole target population in
each region and (b) for the subpopulations of the three
blocks in the stepped wedge design (see results).
Comparison of participants and non participants
Profiles of participants and non participants will be stu-
died to evaluate how people perceive the screening pro-
gramme and whether high-risk groups have been
reached. During the screening, detailed background
information about participants and non participants is
collected by means of online questionnaires and mail.
Screening test results are monitored in a central data-
base, which includes the data from the online question-
naires. Participants who log in to the website are asked
about education, sexual experience, and history of STI.
After the test results have become available, participants
who tested positive are asked about their doctor’sc o n -
sultation and Chlamydia treatment for themselves and
their current partners; they are also asked whether they
informed recent ex-partners and whether they made use
of the option to enlist them for a screening invitation.
A sample of participants (n = 5500) are to receive an
additional e-mail questionnaire in which they can give
their opinion of the set-up of the screening and the infor-
mation provided so that we can assess the acceptability of
the screening procedures. In addition, a sample of non-
participants (n = 13,500) are to be approached by surface
m a i lt oa n s w e raq u e s t i o n n a i r ea b o u tw h yt h e yd i dn o t
participate, their opinion of the screening, and personal
characteristics.
From Chlamydia positivity to Chlamydia prevalence
We will estimate the Chlamydia trachomatis prevalence
in the target population from the positivity rates by extra-
polation of the screening participants’ results to the
whole target population, by comparing the participant
and non participant characteristics including age, gender,
region of origin, and sexual behavioural information.
Other factors such as re-infection rates and treatment
will also be noted.
In South Limburg, we will use an extra selection tool
a i m e da ti n c l u d i n gp a r t i c i p a n ts with a potentially higher
risk of Chlamydia to increase the cost-effectiveness of
screening in areas with a lower population density and a
lower prevalence of Chlamydia. This tool will be evaluated
Figure 3 Risk stratification and cluster randomization: map of Amsterdam. The map shows the division into clusters (neighbourhoods)
with an indication of Chlamydia risk levels and randomized stratification into blocks A, B, and C.
van den Broek et al. BMC Infectious Diseases 2010, 10:89
http://www.biomedcentral.com/1471-2334/10/89
Page 5 of 12for its effect on the participation and positivity rates of
subgroups in the population [12,13].
Furthermore, other data sources in the intervention
regions will be more widely studied for Chlamydia pre-
valence and sexual behaviour in the Netherlands. These
data sources include the STI surveillance in STI centres,
general practitioner (GP) networks, and laboratory and
hospital registers. Combined effects from screening out-
comes and Chlamydia-testing at these sites will be
taken into account. Similar analyses will be conducted
for self-reported PID. Trends of PID will also be studied
within the surveillance networks of GPs and hospitals.
Prediction model for future effects of screening on
prevalence
Data collected during the screening will be used in com-
bination with other datasets and literature data (e.g. on
sexual behaviour, transmission risks, and the likelihood
of developing complications such as PID) for an epide-
miological model of transmission dynamics of Chlamy-
dia [15,16]. This dynamic epidemiologic model will
be used to compute the estimated numbers of new
infections and avoided complications for different
intervention options. The model - a simulation model
based on individuals - uses data such as age, gender,
sexual activity (high or low), status of infection (not
infected, symptomatic, or asymptomatic), duration of
infection, the number and identity of partners (casual or
steady), and the duration of relationships. The annual
incidences, as calculated with the model, are then used
as input for a Markov model that describes the potential
long-term consequences of infection [17-19]. The varia-
tion of input parameters will help us address important
questions about who to screen and how frequently to
do so.
The screening programme and evaluation have been
approved by a Medical Ethics Committee of the VUmc
in Amsterdam (METc number: 2007/239). Participants
provide online informed consent.
Results
During the first screening round, from April 2008 to
February 2009, a total of 261,025 people were invited
(blocks A and B). Altogether, 52,741 people (20.2%)
requested a Chlamydia test package online, and 41,638
Figure 4 Risk stratification and cluster randomization: map of Rotterdam. The map shows the division into clusters (neighbourhoods) with
an indication of Chlamydia risk levels and randomized stratification into blocks A, B, and C.
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a sample to the laboratory.
Comparison of findings per region and per block of the
stepped wedge design
The participation rates were 17.0% in Amsterdam, 15.2%
in Rotterdam, and 11.0% in South Limburg - significantly
different rates in the three regions (c
2: p < 0.001; Figure
5 and Table 1). The participation rate in South Limburg
was lower because of the selection-by-risk score: 22.5% of
the South Limburg invitees went online to fill in the risk
score, of whom 63% had a score high enough to request
a test package. The positivity rate among participants in
Amsterdam (3.6%) was lower than in Rotterdam (5.1%).
In South Limburg, the positivity rate was also 5.1% due
to the selective inclusion of people at risk. Block A and
block B in Amsterdam had significantly different partici-
pation and positivity rates (c
2: p < 0.001). In Rotterdam,
the participation rates in the two blocks were similar, but
the positivity rates differed (p = 0.01).
Figure 5 Participation rates (A) and positivity rates (B) in year 1 of the Chlamydia screening, per region and for blocks A and B of the
stepped wedge design. Error bars show 95% confidence intervals.
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The participation and positivity varied greatly per geo-
graphical cluster. In Amsterdam, participation rates var-
ied from 8% to 26% and positivity rates from 1% to 15%
per cluster. In Rotterdam, the ranges were 8% to 25%
and 1% to10%, respectively, and in South Limburg 5% to
19% and 2% to 9%, respectively. The community risk
estimates per cluster, based on demographic characteris-
tics of age, ethnicity, level of income, and urbanization,
resulted in three distinct groups of clusters in each
region. High-risk clusters in Rotterdam and Amsterdam
had lower participation rates, but higher positivity rates
than medium- and low-risk clusters (p < 0.001). In
South Limburg, where participants were selected by risk
score, the high- and medium-risk clusters had higher
participation rates than the low-risk clusters (p < 0.001),
while the positivity rates did not differ (p =0 . 8 ;
Figure 6).
Prediction of detectable decrease after screening
At forehand, contour plots were made with expected
participation rates (30%) against the decline in mean
prevalence after one or two screening rounds, for each
region and for the subpopulations of the blocks in the
Table 1 Participation and positivity rates in the first screening round and minimal detectable difference in positivity
between rounds 1 and 2 at a power of 80%
Number
invited
Participation rate
% (95% CI)
Positivity rate
% (95% CI)
Detectable decline of
positivity rate (in % after screening)
Amsterdam Block A 25,121 18.0 (17.5-18.5) 2.9 (2.5-3.5) Block A versus block B 0.9
Block B 114,937 16.8 (16.6-17.0) 3.7 (3.5-4.0) Block A versus block C 1.2
Overall 140,058 17.0 (16.8-17.2) 3.4 (3.8-0.2) Round 1 to round 2 0.5
Rotterdam Block A 17,929 14.8 (14.2- 15.3) 6.2 (5.3-7.2) Block A versus block B 1.4
Block B 89,877 15.3 (15.0-15.5) 4.9 (4.5- 5.2) Block A versus block C 1.8
Overall 107,806 15.2 (15.0-15.4) 5.1 (4.7-5.4) Round 1 to round 2 0.8
South Limburg* Block A 13,124 11.0 (10.5-11.5) 5.1 (4.1-6.4) Block A versus block B 1.9
Overall (only block A in first round) Round 1 to round 2 1.2
* with application of a selection based on risk scores
Figure 6 Participation rates (bars) and positivity rates (lines) in year 1 of the Chlamydia screening per region and for the three
community risk levels estimated on the basis of demographic characteristics. Error bars show 95% confidence intervals; H = high, M =
medium, L = low.
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the assumption of an overall Chlamydia prevalence of 5%
at the start of the screening, these plots showed that the
cluster set-up has sufficient power (80%) to detect a reduc-
tion of the Chlamydia prevalence from 5% in screening
round 1 to 4% in screening round 2, provided that the par-
ticipation rates were at least 10% in Amsterdam and Rot-
terdam and at least 25% in South Limburg. For sufficient
power to detect a 1% difference in prevalence between the
three blocks, the participation rates should be higher: 25%
to 45%. The effect of screening on the prevalence rate
should be robust if participation rates of the overall
regions are between 10% and 20%.
By using the real participation- and Chlamydia positivity
rates from the first screening round (Table 1), we deter-
mined the minimal decline needed to find a significant
effect of screening on Chlamydia positivity. In Amster-
dam, a decrease of overall positivity from 3.4% in the first
round to 2.9% in the second round (a proportional decline
of 15% from the first round positivity) would be signifi-
cant; in Rotterdam a decline from 5.1% to 4.3% (16%) and
in South Limburg from 5.1% to 3.9% (24%) would be sig-
nificant. However, to show differences between the blocks,
a steeper decline is needed, i.e. for comparing block A
with block C in Amsterdam, a decrease of 1.2% in positiv-
ity (35% of that in the first round) is needed in the second
round at a participation rate of 17%. In Rotterdam and
South Limburg, similar proportional declines are necessary
at current participation rates to prove any effect of one
screening round comparing the positivity in blocks A,
B, and C.
Response to questionnaires
The response rate to the general questionnaire (at login
on the website) was high: 60% of the participants. In
total, 30,517 people responded, and most of them (82%)
were participants, but some requested a test package
and did not send it back (16%), and 2% filled in the
questionnaire without requesting a package. About 750
people who tested positive (43%) completed the ques-
tionnaire about treatment. The acceptability question-
naire had a response of 63% (n = 3500), and the
nonresponse questionnaire, 15% (n = 2050). The
women’s response rate was higher than that of men for
all questionnaires. Younger people (< 20 years old) more
often replied than did older people (20-29 years old).
Discussion and Conclusions
Invitations for the first round of the Chlamydia screen-
ing in Amsterdam, Rotterdam, and South Limburg were
completed by the end of February 2009. Nearly one of
six 16 to 29-year-olds in the three participating regions
have been screened in this first round, and one in 25
participants tested positive for Chlamydia.T h ef i n a l
impact evaluation of the programme is expected when
two screening rounds have been completed in 2010.
However, the findings from the 1st year allow us to
review (the expected power of) our evaluation design.
Figure 7 Detectable differences in prevalences between screening rounds 1 and 2. Power levels are noted on lines, and 4%, 5%, and 6%
prevalence rates in screening round 1 (p0) are presented as a function of the participation rate (sample fraction): A, simulations for Amsterdam,
overall and B, comparison of blocks A and C.
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30% in the Pilot Ct (both register based) which was
expected as our programme is selective in its nature:
only for sexually actives and for Limburg a further selec-
tion by the prediction rule was incorporated in the pro-
gramme. Moreover, the programme used test kit
requests via internet instead of directly sending test kits.
We want to caution about (inter)national comparisons
of participation rate as programme designs may differ
and denominators and test kit offering may not be com-
parable [10]. For instance, in opportunistic programmes,
acceptance of test-offer may be presented as coverage;
sometimes denominators include only sexually actives
or are not population-based but reflect attendees of
health facilities. The overall 16% participation rate is
based on the total number of invitees which includes
people who are not sexually active yet.
The overall positivity rate of 4.2% was higher than that
of the pilot CT study (2.0% overall and 3.2% in highly
u r b a n i z e dr e g i o n s )[ 7 ] ,t h eA m s t e r d a mp r o g r a m m e
(3.4%) [20] and the UK programme (3.1%) [21], suggest-
ing an adequate (self) selection which will benefit cost-
effectiveness of the programme.
Using simulations, we have confirmed that, with parti-
cipation and positivity rates as observed in the 1st year
of screening, we will be able to show a significant ‘over-
all’ effect of one screening round on the Chlamydia pre-
valence if it decreases by about 15% in the cities and
25% in South Limburg. At the level of the blocks in the
stepped wedge design, an effect might not be detectable
with statistical significance after two screening rounds,
unless the prevalence diminishes by one-third or more.
The effect of screening might better be evaluated
separately in the three regions of Amsterdam, Rotter-
dam, and South Limburg because participation and posi-
tivity rates in the regions were significantly different.
Blocks A and B of the cluster-randomized stepped
wedge design also showed different participation and
positivity rates in this first round. The randomization of
clusters was stratified by risk level, but this apparently
did not result in completely similar groups within one
region. These differences should be taken into account,
and multilevel analysis should be used to compare pre-
and post-screening prevalence (extrapolation of findings
in blocks A, B, and C).
There was a large variation in participation and posi-
tivity rates at the lowest level among the clusters.
Beforehand, we assumed a positivity rate per cluster
between 0% and 10% (for simulations). Most clusters
remained within this range (only one cluster in Amster-
dam had a positivity rate above 10%). The assignment of
the risk levels (high, medium and low community risk,
based on the criteria of age, ethnicity, income profile,
and urbanization) created different groups of clusters, at
least in the two cities. Participation was lower and posi-
tivity was higher in high-risk clusters, as can be
expected, and as was also found in the UK [21]. Study-
ing the effect of screening within these different risk
levels will provide food for thought for further popula-
tion screening targets.
Limitations
The stepped wedge design facilitates the analysis of the
effect of multiple screening rounds on test positivity in
the light of modelling Chlamydia transmission and esti-
mating cost-effectiveness, but will also have limitations.
First, equal sizes of the three blocks in Amsterdam and
Rotterdam would have increased the power of the com-
parisons between blocks, but would deviate too much
from the agreed two screening rounds for everyone. Sec-
ondly, potential bias is caused by the fact that the parti-
cipation and the receiving of a Chlamydia positive or
-negative test result in the first screening round may
affect the participation in the subsequent rounds. This
can be reviewed by comparing consistent non respon-
ders, repeat participants, and one-time participants.
The characteristics of participants and non responders
(gender, age, ethnic background, sexual activity, et
cetera) will be used to predict the Chlamydia population
prevalence from the Chlamydia positivity rate by model-
ling. The success of these predictions will depend on the
outcomes of the non response study: non responders are
the largest group in our population, and estimating the
proportion of those not responding because they are not
at risk (because they are not, or not yet, sexually active
or are in a long-term faithful relationship) is very impor-
tant. One in 15 non responders received a questionnaire,
and 15% replied. For those, information about the sexual
history is available. However, basic characteristics (gen-
der, age, ethnic group, and cluster) from the population
registers are available for all non responders. The parti-
cipant response rates to the online general question-
naire, the acceptability study via e-mail (60% or more)
and the online treatment questionnaire were higher
than response rates to the treatment questionnaire
among those who tested positive (43%). The question-
naires will provide detailed insight into ‘who participated
when and why’ (and who did not), as well as informa-
tion about behavioural characteristics such as sexual
behaviour, number of sexual partners, and condom use.
Opportunities
The stepped wedge design has the advantage that the
first screened block(s) can be used for a baseline preva-
lence measurement, so that extra surveys (before and
after screening) that could seriously interfere with parti-
cipation and positivity in the screening population,
could be avoided.
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screening would provide good primary evidence of effec-
tiveness [3]. Further interpretation and modelling are
needed to predict the effects of multiple (more than
two) screening rounds. Existing predictive models
[15,16] will be updated with the findings from the
screening and recent literature. Much information will
be obtained from the CSI database, which will include
around 300,000 invitees and, as expected on the basis of
the first results, 40,000 to 50,000 participants per year.
The large-scale CSI-programme, as implemented in the
Netherlands, provides a unique opportunity to assess
the effectiveness of a systematic, population-based
screening offered to young people for reducing the
Chlamydia prevalence - and self-reported PID preva-
lence - in the screened population and the population at
large.
The outcomes can be compared to other ongoing
initiatives such as opportunistic screening as practised
in the UK, Sweden, and the USA [22], population-based
studies such as those in Sweden [23], Denmark [5], and
the Netherlands [7,24], and various RCTs [4,5]. This
may provide the necessary evidence for the effectiveness
of register-based programmes [3]. In conclusion, we will
use a combination of methodologies to investigate inno-
vative aspects of the design of CSI. We expect the pro-
ject to yield new insights into the impact of Chlamydia
screening, epidemiological trends, and screening that
makes use of the Internet. The comprehensive evalua-
tion will enable national health authorities to decide
whether to implement nationwide Chlamydia screening
in the Netherlands.
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